Literature DB >> 7525725

Protective cytotoxic T lymphocytes are induced during murine infection with Chlamydia trachomatis.

M N Starnbach1, M J Bevan, M F Lampe.   

Abstract

T cell responses are often an important component in immunity to organisms that replicate intracellularly. Cytotoxic T lymphocyte (CTL) recognition of peptide Ag in the context of MHC class I molecules results in lysis of infected cells and the release of cytokines including IFN-gamma. Members of the genus Chlamydia are obligate intracellular pathogens that cause blindness and sexually transmitted disease worldwide. Even though it replicates within a membrane-bound vacuole, Chlamydia trachomatis may elicit a CTL response if Chlamydia Ags are present in the cytoplasmic compartment where they can be processed for presentation and bound by MHC class I. In this study, we characterized a CTL line derived from mice infected with C. trachomatis. This CTL line is specific for, and able to lyse, Chlamydia-infected cells. The peptide epitope recognized by this CTL line is present on infected cells, and is presented to the CTL by the classical MHC class I molecule H-2 Ld. Adoptive transfer of this CTL line into an infected mouse affords protection, and this protection requires the activity of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525725

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  65 in total

Review 1.  Immunity to murine chlamydial genital infection.

Authors:  Richard P Morrison; Harlan D Caldwell
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

2.  T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.

Authors:  X Yang; R Brunham
Journal:  Can J Infect Dis       Date:  1998-03

3.  Failure to detect HLA-A*6802-restricted CD8+ T cells specific for Chlamydia trachomatis antigens in subjects from trachoma-endemic communities.

Authors:  O S Mahdi; H C Whittle; H Joof; D C Mabey; R L Bailey
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

4.  Acquired immunity to Chlamydia pneumoniae is dependent on gamma interferon in two mouse strains that initially differ in this respect after primary challenge.

Authors:  J M Vuola; V Puurula; M Anttila; P H Mäkelä; N Rautonen
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

5.  A role for interleukin-6 in host defense against murine Chlamydia trachomatis infection.

Authors:  D M Williams; B G Grubbs; T Darville; K Kelly; R G Rank
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice.

Authors:  J U Igietseme; I M Uriri; S N Kumar; G A Ananaba; O O Ojior; I A Momodu; D H Candal; C M Black
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

7.  Murine cytotoxic T lymphocytes induced following Chlamydia trachomatis intraperitoneal or genital tract infection respond to cells infected with multiple serovars.

Authors:  M N Starnbach; M J Bevan; M F Lampe
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  CD4+ T cells play a significant role in adoptive immunity to Chlamydia trachomatis infection of the mouse genital tract.

Authors:  H Su; H D Caldwell
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection.

Authors:  R P Morrison; K Feilzer; D B Tumas
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

10.  Cytokine expression pattern in the genital tract of Chlamydia trachomatis positive infertile women - implication for T-cell responses.

Authors:  B S Reddy; S Rastogi; B Das; S Salhan; S Verma; A Mittal
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.